DMAC实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (21 May 2024 @ 04:00):

Stats
今日成交量	6 661.00
平均成交量	40 527.00
市值	116.17M
EPS	$0 ( 2024-05-08 )
下一个收益日期	( $-0.160 ) 2024-08-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.10
ATR14	$0.0180 (0.60%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-22	Lorianne Masuoka K.	Buy	285 000	Stock option (right to buy)
2024-01-22	Lorianne Masuoka K.	Buy	0
2024-01-02	Semba Charles Pauling	Buy	9 375	Voting Common Shares, no par value per share
2024-01-02	Kuntz Richard	Buy	14 285	Voting Common Shares, no par value per share
2024-01-02	Pilnik Richard D.	Buy	30 357	Voting Common Shares, no par value per share

INSIDER POWER
54.00
Last 91 transactions
Buy: 8 059 792 \| Sell: 2 870 847

DiaMedica Therapeutics 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

DiaMedica Therapeutics 财务报表

Annual	2023
营收:	$0
毛利润:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2023
营收:	$0
毛利润:	$-30 000.00 (0.00 %)
EPS:	$-0.600

FY	2022
营收:	$0
毛利润:	$-25 000.00 (0.00 %)
EPS:	$-0.520

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.650

Financial Reports:

No articles found.

DiaMedica Therapeutics Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

实时更新： DiaMedica Therapeutics [DMAC]

Upcoming Earnings Alert

DiaMedica Therapeutics Options Data

Calls

Puts